Sandeep Bhuta

Sandeep Bhuta

Auto-generated profile, based on publicly available information

Sandeep Bhuta

School of Medicine and Dentistry, Griffith University, Gold Coast Campus, Southport, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2011 in Journal of Neuroimaging
Verified
Journal Article
Closed access
PDF file
RRRichard J. Robinson
Richard J. Robinson
SBSandeep Bhuta
Sandeep Bhuta

18 April 2012 in British Journal Of Neurosurgery
Verified
Journal Article
Closed access
CHCharlie Hsu
Charlie Hsu
GKGigi Kwan
Gigi Kwan
QLQueenie Lau
Queenie Lau
SBSandeep Bhuta
Sandeep Bhuta
Background. Rosette-forming glioneuronal tumour (RGNT) is a rare and novel brain tumour. We present a case of rosette forming glioneuronal tumour of the fourth ventricle and highlight the imaging and histological features of this tumour entity. We also performed a comprehensive review of the imaging features, treatments and outcomes of all past cases and make recommendations on diagnosis and management. Method. We conducted a PUBMED search using the words ‘rosette forming glioneuronal tumour’, and identified 48 cases of rosette forming glioneuronal tumour. We reviewed the location, imaging features of this rare tumour entity as well as the treatment and follow-up. We also present a case of a 42-year-old man with an incidental finding of a solid-cystic midline mass in the posterior fossa at the level of fourth ventricle with morphological features and immunohistochemical characteristic of a RGNT (WHO Grade I). Findings. RGNT is commonly found in association with the fourth ventricle often with local extension; however, it is known to occur at sites outside of its usual location. RGNT can demonstrate solid, cystic or mixed features on MRI and frequently shows focal contrast enhancement. It is often associated with an element of hydrocephalus. Gross or subtotal tumour resection was the most common treatment of choice. Due to the intimate relationship of these tumours to key neural structures in the cerebellum, variable degrees of postoperative neurological deficits were reported in half of the patients. Among the reported cases, no evidence of recurrence following gross or subtotal resection of tumour was seen in the majority of patients. However, owing to lack of lengthy follow-up, we recommend routine imaging follow-up. Conclusion. Knowledge of this tumour is of importance as they are relatively slow growing and exhibit benign histological characteristics, thus depending on its location maybe amenable to gross total resection.

8 April 2015 in Japanese Journal of Radiology
Verified
Journal Article
Closed access
PDF file
DSDalveer Singh
Dalveer Singh
CHCharlie Chia-Tsong Hsu
Charlie Chia-Tsong Hsu
GKGigi Nga Chi Kwan
Gigi Nga Chi Kwan
SBSandeep Bhuta
Sandeep Bhuta
MSMatt Skalski
Matt Skalski
RJRhondda Jones
Rhondda Jones

7 August 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
ULUnnah Leitner
Unnah Leitner
SCSin Hong Chew
Sin Hong Chew
JBJessica Blanch
Jessica Blanch
MVMegha Viswanathan
Megha Viswanathan
SPSasha Patil
Sasha Patil
SBSimon Broadley
Simon Broadley
Background and objectives: Multiple sclerosis (MS), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-Ab + ve NMOSD), and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are demyelinating diseases with differing pathophysiological processes and treatments. The objective of this study was to compile a comprehensive list of MRI lesions, and to quantify the utility of these lesions in distinguishing between these conditions. Methods: We searched for articles comparing MRI lesion frequency in MS, AQP4-Ab + ve NMOSD, MOGAD and healthy controls. Bayesian network meta-analysis together with pairwise and pooled case-case comparison analyses to develop sensitivity, specificity, and positive predictive values were undertaken. Results: Sixty-six articles were reported on 2933 MS, 3296 AQP4-Ab + ve NMOSD, and 1559 MOGAD cases, and 561 healthy controls. MRI lesions associated with MS were: periventricular T2, subcortical white matter T2, Dawson's finger, U-fibre T2 lesion, posterior spinal column T2, inferior temporal T2, cortical T2, brain T1 hypointensity (black holes), peripheral spinal cord T2, pons T2, unilateral optic nerve T2 and brain gadolinium enhancing lesions. Optic chiasm T2, LETM, bright spotty spinal cord T2, area postrema T2, hypothalamic T2, spinal cord atrophy and optic tract T2 lesions were associated with AQP4-Ab + ve NMOSD. Conus medullaris T2, fluffy, perineural enhancement, peri-ependymal 3rd ventricle T2 and peri-ependymal 4th ventricle T2 lesions were associated with MOGAD. Discussion: This review identified MRI features supportive of a diagnosis of MS, NMOSD or MOGAD, and has clarified the diagnostic utility of various MRI lesion characteristics, to aid in future clinical decision-making and guide future approaches to research.

1 July 2015 in Pediatric Neurology
Verified
Journal Article
Closed access
CHCharlie Chia-Tsong Hsu
Charlie Chia-Tsong Hsu
GKGigi Nga Chi Kwan
Gigi Nga Chi Kwan
SBSandeep Bhuta
Sandeep Bhuta

1 January 2015 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
YHYu-Ting Huang
Yu-Ting Huang
AKAravind S. Ravi Kumar
Aravind S. Ravi Kumar
SBSandeep Bhuta
Sandeep Bhuta
Purpose There is evidence that the status of human papilloma virus subtype 16 (HPV-p16) alters the prognosis of patients with oropharyngeal squamous cell cancer (OSCC). We sought to establish whether there is a relationship between HPV-p16 status and 18F-FDG uptake in the prognosis of OSCC. Materials and methods Patients with newly diagnosed OSCC at our institution between June 2011 and June 2012 were retrospectively evaluated. All patients underwent a baseline 18F-FDG PET/computed tomographic scan and HPV-p16 testing. Tumour maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) and total glycolytic activity (TGA) [defined as metabolic tumour volume (MTV) multiplied by SUVmean] were measured. All PET/computed tomographic scans were reviewed on a Siemens Syngo.via (version VA11B_HF03) workstation. A designated operator defined the region of the primary tumour with the MTV segmented by 40% of the SUVmax fixed threshold method. Results Seventy-nine patients aged 27–84 years met the criteria for inclusion in the study. The types of primary tumour were tonsillar squamous cell carcinoma in 48% and base of tongue squamous cell carcinoma in 29%. The mean SUVmax was 17.5 and 17.7 in HPV-p16-positive and HPV-p16-negative groups, respectively (P=0.90). The mean MTV was 8.36 and 7.07 ml in HPV-p16-positive and HPV-p16-negative patients, respectively (P=0.42). The mean TGA values were 96.3 and 82.5 g among the HPV-p16-positive and HPV-p16-negative patients (P=0.54). There was no significant difference between HPV-p16 status and tumour grading for any of the imaging markers. Conclusion There were no statistically significant differences between HPV-p16-positive and HPV-p16-negative OSCC for any of the metabolic imaging markers (SUVmax, SUVmean, MTV and TGA) measured in this study.